Patents by Inventor Frank Ludicke

Frank Ludicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for contraception
    Patent number: 5824667
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.020 mg of ethinylestradiol;and a gestagen selected from0.25 to 0.30 mg of drospirenone and0.1 to 0.2 mg of cyproterone acetate,followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: October 20, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
  • Mounting to establish a basic reference for measuring machines and machine tools
    Patent number: 4777728
    Abstract: For the mounting of measuring scales or straight-edges, they are clamped on balls (2, 6) rollably retained within small regions, which form a lengthwise guide and are fixed relative to their mounting (3) at a single point (5).
    Type: Grant
    Filed: August 20, 1987
    Date of Patent: October 18, 1988
    Assignee: Carl-Zeiss-Stiftung, Heidenheim/Brenz
    Inventor: Frank Ludicke
  • Composition for contraception
    Patent number: RE37564
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: February 26, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
  • Composition for contraception
    Patent number: RE37838
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: September 10, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
  • Composition for contraception
    Patent number: RE38253
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: September 16, 2003
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
  • Composition for contraception
    Patent number: RE43916
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 8, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
  • Composition for contraception
    Patent number: RE44159
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: April 16, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke